secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2022-07-15T23:59:59+00:00
Accession:  0000950142-22-002222
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRXP receives Nasdaq delisting warning for bid price below $1; appoints Stephen Willard as CEO
--------------------------------------------------------------------------------

- Nasdaq notified NRXP on July 12, 2022 of non-compliance with minimum bid price rule (below $1 for 30 days); 180-day cure period to Jan 9, 2023.
- Stephen Willard appointed CEO and director effective July 12, 2022; base salary $500k/yr, target bonus $250k, 1M restricted shares vesting over 3 years.
- Interim CEO Robert Besthof returns to roles as Head of Operations and Chief Commercial Officer.
- Mr. Willard previously CEO of Cellphire Therapeutics and Flamel Technologies; also a National Science Board presidential appointee (2018-2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222002222/0000950142-22-002222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000095014222002222/eh220269223_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950142-22-002222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer